Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-002K in Ischemic Cardiomyopathy
NCT04695522Phase 1Unknown
- Sponsor
- The University of Osaka
- Start
- Nov 2019
- Primary completion
- Apr 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ADR-002K in ischemic cardiomyopathy (ICM) (2 arms), sponsored by The University of Osaka. Primary endpoints: Number of participants with Adverse event at 26 weeks, Amount of change in late gadolinium contrast-enhanced area at 26 weeks and 1 more. Status: unknown.
02
Drugs
ADR-002K
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT04695522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695522.